首页|基于数据挖掘法探讨专利中药复方治疗强直性脊柱炎的组方规律

基于数据挖掘法探讨专利中药复方治疗强直性脊柱炎的组方规律

扫码查看
目的 基于国家专利中药复方,探究中医药治疗强直性脊柱炎(AS)的用药及组方规律。方法 收集建库至2024年5月中国专利公布公告网站上公开发布的关于中药复方治疗AS的专利,采用Excel 2010软件及中医传承辅助系统(V2。5)对中药频次、性味归经进行统计,采用关联规则、复杂系统熵聚类进行分析及可视化处理,并对结果进行新方组合。结果 共纳入符合专利复方194项,包含内外共用专利复方5项,排除中药复方中含有相同药物的处方后,获得有效中药复方149首,涉及中药531味。其中排名前20位的主要是当归、狗脊、甘草、杜仲、鸡血藤、怀牛膝、独活、白芍、威灵仙、桑寄生、熟地黄、续断、川芎、桂枝、黄芪、红花、羌活、土鳖虫、防风、丹参。药性多为温、寒、平性药,药味多为甘、苦、辛味药,归经多为肝、肾、脾经;应用关联规则分析,将支持度设置为20,置信度为0。6,共得到12组高频药物组合,包含中药10味(频次≥20),采用降序排列依次为"杜仲-狗脊、白芍-狗脊、杜仲-当归"等;并得到6个关系密切药物组合,降序依次排列为"白芍-狗脊""续断-狗脊""熟地黄-当归"等;采用无监督熵层次聚类算法分析,得到14组新方核心组合,在此基础上,共获得新方7个。结论 专利中药复方治疗AS以补益肝肾、健脾祛湿、活血化瘀止痛为主,本研究分析了中药复方专利治疗AS的组方规律,对临床中治疗AS的遣方用药和新药开发提供一定参考。
Exploring the formulation rules of patent traditional Chinese medicine compound in the treatment of ankylosing spondylitis based on data mining method
Objective To explore traditional Chinese medicine treatment of ankylosing spondylitis(AS)of drug and formula based on the national patent traditional Chinese medicine compound.Methods The data of the patented traditional Chinese medicine compound for the treatment of AS were retrieved from the database of China Patent Publication Network of the State Intellectual Property Office from the inception to May,2024.Microsoft Office Excel 2010 and the Traditional Chinese Medicine Inheritance Platform V 2.5 were used for carry out the statistics of frequency,nature,flavour,and channel tropism of Chinese medicine,and the results were analyzed and visualized by association rules and systematic cluster analysis,and the results were combined with new formulas.Results A total of 194 patent compounds were included,involving five patent compounds shared internally and externally,and 149 effective traditional Chinese medicine compounds were obtained after excluding prescriptions containing the same drug in traditional Chinese medicine compounds,with involving 531 kinds of drugs.The top 20 were mainly Chinese Angelicae Sinensis Radix,Cibotii Rhizoma,Glycyrrhizae Radix Et Rhizoma,Eu-commiae Cortex,Spatholobi Caulis,Achyranthis Bidentatae Radix,Angelicae Pubescentis Radix,Paeoniae Radix Alba,Clematidis Radix Et Rhizoma,Taxilli Herba,Rehmanniae Radix Praeparata,Dipsaci Radix,Rhizoma Ligustici Chuanx-iong,Cinnamomi Ramulus,Astragalus propinquus,Carthami Flos,Notopterygii Rhizoma Et Radix,Eupolyphaga Stele-ophaga,Saposhnikoviae Radix,Salviae Miltiorrhizae Radix Et Rhizoma.The nature of drug was mainly warm,cold,and mild,the flavour of drug was mostly sweet,bitter,and pungent.Which belonged to mostly liver,kidney,and spleen meridians.Association rules analysis obtained 12 groups of high frequency drug combinations and based on the support degree was set to 20,and the confidence level was 0.6,including 10 traditional Chinese medicines(frequency ≥ 20),which were ranked in descending order as"Eucommiae Cortex-Cibotii Rhizoma","Paeoniae Radix Alba-Cibotii Rhizoma","Eucommiae Cor-tex-Angelicae Sinensis Radix",etc.Six closely related drug combinations were obtained,which were ranked in descending order as"Paeoniae Radix Alba-Cibotii Rhizoma","Dipsaci Radix-Cibotii Rhizoma","Rehmanniae Radix Praeparata-Angelicae Sinensis Radix"and so on.Using unsupervised entropy hierarchical clustering algorithm,14 groups of new for-mula core combinations were obtained,and seven potential new methods were obtained on this basis.Conclusion The main therapeutic methods of the patented Chinese medicine compound in the treatment of AS are tonifying liver and kidney,in-vigorating spleen eliminating dampness and promoting blood circulation for removing blood stasis and relieving pain.This study analyzes the formula rules of the patented traditional Chinese medicine compound for the treatment of AS,which pro-vides a certain reference for the formulation and new drugs development for the treatment of AS in clinical practice.

Ankylosing spondylitisData miningTraditional Chinese medicine inheritance assistance systemChinese medicine compoundPatents

吉富涛、张凯、罗俊普、王留辉、霍帅、王彪彪、顾海潮、尹本敬

展开 >

郑州四六○医院骨科中心,河南郑州 450007

云南省中医医院骨四科,云南昆明 650100

强直性脊柱炎 数据挖掘 中医传承辅助系统 中药复方 专利

2024

中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
年,卷(期):2024.21(24)